Scribd
Upload
697 views2 pages

GLP1ReceptorInjectablesPC 2024

This document summarizes several GLP-1 receptor agonists and insulin/GLP-1 receptor agonist combination therapies that are used to treat diabetes. It lists the names of the drugs, their doses, considerations for use such as side effects and warnings, and their effectiveness in lowering blood sugar and promoting weight loss. Two combination therapies are highlighted: Xultophy which combines insulin degludec and liraglutide, and Soliqua which combines insulin glargine and lixisenatide. Both combinations can be dosed once daily via pre-filled pen and are options when target blood sugar levels are not met with basal insulin or GLP-1 receptor agonist therapy alone.

Uploaded by

Dr. Ricardo R.V. de Brito
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
697 views2 pages

GLP1ReceptorInjectablesPC 2024

This document summarizes several GLP-1 receptor agonists and insulin/GLP-1 receptor agonist combination therapies that are used to treat diabetes. It lists the names of the drugs, their doses, considerations for use such as side effects and warnings, and their effectiveness in lowering blood sugar and promoting weight loss. Two combination therapies are highlighted: Xultophy which combines insulin degludec and liraglutide, and Soliqua which combines insulin glargine and lixisenatide. Both combinations can be dosed once daily via pre-filled pen and are options when target blood sugar levels are not met with basal insulin or GLP-1 receptor agonist therapy alone.

Uploaded by

Dr. Ricardo R.V. de Brito
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 2

GLP-1 & GIP Receptor Agonists

Class/Main Action Name Dose Range Considerations


GLP-1 RA - Glucagon exenatide (Byetta) 5 and 10 mcg BID Side effects: nausea, vomiting,
Like Peptide weight loss, injection site reaction.
exenatide XR† 2 mg 1x a week
Receptor Agonist Report signs of acute pancreatitis
(Bydureon) Pen injector - Bydureon BCise
or intestinal blockage (ileus) and
“Incretin Mimetic”
liraglutide (Victoza)*† 0.6, 1.2 and 1.8 mg daily stop med. Increase dose monthly to
• Increases insulin
achieve targets.
release with food
dulaglutide* 0.75, 1.5, 3.0 and 4.5 mg Black box warning: Thyroid C-cell
• Slows gastric
(Trulicity)† 1x a week pen injector tumor warning (avoid if family history
emptying
of medullary thyroid tumor).
• Promotes satiety
semaglutide* 0.25, 0.5, 1.0 and 2.0 mg *Significantly reduces risk of CV
• Suppresses
(Ozempic) 1x a week pen injector death, heart attack, and stroke.
glucagon
†Approved for pediatrics 10-17 yrs
(Rybelsus) 3, 7, and 14 mg daily in a.m.
Oral tablet Take on empty stomach with sip Lowers A1C 0.5 – 1.6%
of water Weight loss: 4-6% body weight loss.
GLP-1 & GIP Tirzepatide 2.5, 5.0, 7.5, 10, 12.5 and 15 mg Side effects: nausea, diarrhea,
Receptor Agonist (Mounjaro) injection site reaction. Report
1x a week prefilled single dose
pancreatitis, signs of intestinal
pen
Activates receptors blockage.
for GLP-1 (see above) Increase dose by 2.5 mg once Black box warning: Avoid if family
& Glucose- monthly to reach targets. history of medullary thyroid tumor.
dependent
Insulinotropic Lowers A1C ~ 1.8 - 2.4%
Polypeptide (GIP). Weight loss: 7-13% body weight loss
at max dose.
DiabetesEd.net © 2024
PocketCards are updated twice yearly.

Insulin/Injectable Combos Scan QR code to download or


order the latest version.

Name Combines Considerations


IDegLira* Insulin degludec Xultophy 100/3.6 pre-filled pen = 100 units IDeg / 3.6 mg liraglutide per mL
(IDeg or Tresiba) Once daily injection – Dose range 10 to 50 =
Xultophy
Ultra long insulin 10 – 50 units IDeg + 0.36 -1.8 mg liraglutide
100/3.6
+ Recommended starting dose:
Liraglutide • 16 IDegLira (= 16 units IDeg + 0.58 mg liraglutide)
(Victoza) Titrate dose up or down by 2 units every 3-4 days to reach target.
GLP-1 Receptor Supplied in package of five single-use 3mL pens.
Agonist (GLP-1 RA) Once opened, good for 21 days.

iGlarLixi* Insulin glargine Soliqua 100/33 Solostar Pen = 100 units glargine / 33 μg lixisenatide per mL
(Lantus) Once daily injection an hour prior to first meal of day.
Soliqua
Basal Insulin Dose range 15 – 60 = 15-60 units glargine + 5 – 20μg lixisenatide
100/33
+ Recommended starting dose:
• 15 units if not meeting glucose target on 30 units basal insulin or GLP-1 RA
Lixisenatide • 30 units if not meeting glucose target on 30-60 units basal insulin or GLP-1 RA
(Adlyxin) Titrate dose up or down by 2-4 units every week to reach target.
GLP-1 Receptor Supplied in package of five single-use 3mL pens.
Agonist Once opened, good for 14 days.

*Discontinue basal insulin /GLP-1 RA therapy before starting. If dose missed, resume with next usual scheduled dose.

Observe precautions of each component drug. DiabetesEd.net © 2024

You might also like